Clinical trials: Pancreatic Cancer Stage II
Pancreatic Cancer
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00066677
- Testing
- rhuMAB-VEGF, docetaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This randomized phase III trial is studying gemcitabine and bevacizumab to see how well they work compared to gemcitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00088894
- Testing
- gemcitabine hydrochloride, bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
This is a research study for pancreatic cancer. One way of improving the results of current standard treatments is to try new approaches.
- Trial name
- NCT00593866
- Testing
- INTENSITY MODULATED RADIOTHERAPY, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
The main purpose of this study is to learn whether or not the combination of gemcitabine, bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic cancer. Bevacizumab is a new anti-cancer drug.
- Trial name
- NCT00366457
- Testing
- Bevacizumab, Erlotinib, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability.
- Trial name
- NCT01531712
- Testing
- Gemcitabine, Radiotherapy, Tarceva
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Institut Català d'Oncologia
Metastatic Pancreatic Cancer
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.
- Trial name
- NCT00222469
- Testing
- bevacizumab, gemcitabine, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT02565641
- Testing
- Capecitabine, Gemcitabine
- Where
- 7 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Unresectable Pancreatic Carcinoma
Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients
This is a multicenter center, 2-arms prospective randomized phase II trial which evaluates whether tocilizumab with gemcitabine/nab-paclitaxel is more effective than gemcitabine/nab-paclitaxel.
- Trial name
- PACTO (NCT02767557)
- Testing
- Tocilizumab, Gemcitabine, nab-Paclitaxel
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 147 people
- Sponsor
- Herlev Hospital
Pancreatic Cancer
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
This study is a prospective, single-arm, two-cohort phase II clinical study. It is expected to enroll 48 patients with advanced or metastatic pancreatic cancer who have failed prior treatment with irinotecan-containing regimens…
- Trial name
- NCT06700603
- Testing
- Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
- Volunteers
- 48 people
- Sponsor
- Rui-hua Xu, MD, PhD
Pancreatic Cancer, Pancreatic Carcinoma
Pancreatic Cancer Detection Consortium
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- PCDC (NCT06388967)
- Testing
- PANcreatic cancer Exosome Early detectiON (PANXEON)
- Where
- 13 sites in United States, Japan and 1 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumor, Lung Cancer
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK) profile and preliminary efficacy of intratumoral injection of Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in patients with advanced…
- Conditions
- Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer
- Trial name
- CNSI-Fe(II) (NCT06048367)
- Testing
- CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic…
- Trial name
- CSPAC-48 (NCT06916975)
- Testing
- Adebrelimab, AG
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Jin Xu
Pancreatic Cancer
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have locally…
- Trial name
- NCT00053222
- Testing
- arsenic trioxide
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Chicago
Pancreatic Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gemcitabine may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00010166
- Testing
- gemcitabine hydrochloride, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Locally Advanced Pancreatic Cancer
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
This study is a single-arm, multi-center, open-label prospective phase II clinical study designed to evaluate the efficacy and safety of nab-paclitaxel and S-1 in patients with locally advanced pancreatic cancer.
- Trial name
- NCT03885219
- Testing
- Nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Metastatic Pancreatic Cancer
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
The pancreas cancer is the 4th cause of death. All stage confused, the survival at 5 years is note over 5 %. At metastatic stage, the pancreatic adenocarcinoma is an incurable disease with the survival median of 2-4 months…
- Trial name
- PANOPTIMOX (NCT02352337)
- Testing
- FOLFIRINOX, LV5FU2, FOLFIRI.3
- Where
- 54 sites in France
- Volunteers
- 276 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neuroendocrine Tumor, Carcinoid Tumor
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT01024387
- Testing
- AMG 479
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Ductal Adenocarcinoma
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma…
- Trial name
- NCT05132504
- Testing
- Pembrolizumab, Folfirinox
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine